The application of Novozymes’ VELTIS technology in the drug delivers an extended half-life which will enable patients to inject only once per week. Novozymes business development executive vice
In the unanimous 14 – 0 decision, the AIDAC found that substantial evidence of the safety and effectiveness of SIVEXTRO for the treatment of acute bacterial skin and
Lipoparticles are an enabling technology for the company’s MPS Discovery Engine for isolating monoclonal antibodies (MAbs) against membrane protein targets. Lipoparticles are used to generate conformationally-sensitive, inhibitory MAbs
The Letter Of Intent was signed with another public company listed on the OTCQB exchange. Easton has engaged an attorney who for the past few days and moving
Through these enhancements, Caris Molecular Intelligence will now provide oncologists even more potentially useful treatment information for some of the most challenging cancers, including ovarian, head and neck,
The topic of the Conference was "Different perspectives – one vision: Better healthcare for patients". The Conference helped professionals in the field of medicines, medical device, medical technology,
The uniqueness of this vaccine is that it is produced in ciliates and covers nearly all variations of a certain parasite antigen – a worldwide novelty. This project
Proceeds from the contract will be used to develop an inhaled PDGF receptor kinase inhibitor for the treatment of pulmonary arterial hypertension (PAH). The VITA contract will fund
The claims of the patent cover methods of using biOasis’ brain penetrating drug delivery vector, Transcend, coupled with a lysosomal storage disease enzyme for the treatment of lysosomal
In addition, beginning 24 months after execution of the agreement, CryoLife has the right to acquire the ProCol product line from Hancock Jaffe. Key aspects of transaction: –
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.